Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey - Scorecard - MDSpire

Her son needed a fecal transplant for a fearsome C. diff infection. Getting one required a tortuous journey

  • By

  • Eric Boodman

  • March 23, 2026

  • 0 min

Share

Clinical Scorecard: A Challenging Path to Fecal Transplantation for a Severe C. difficile Infection in Her Son

At a Glance

CategoryDetail
ConditionClostridioides difficile infection (CDI)
Key MechanismsDisruption of gut microbiota leading to C. difficile overgrowth and toxin production.
Target PopulationPediatric patients, particularly those with recurrent CDI.
Care SettingHospital and outpatient settings.

Key Highlights

  • Fecal microbiota transplant (FMT) aims to restore gut microbiota diversity.
  • FDA halted shipments from major stool bank, limiting treatment options.
  • New FDA-approved drugs for CDI are not suitable for children or severe cases.
  • FMT has shown high success rates compared to traditional antibiotics.
  • Cost of new treatments can be prohibitively expensive.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of CDI is based on clinical symptoms and laboratory testing for toxins.

Management

  • Consider FMT for patients with recurrent CDI after standard antibiotic treatments fail.

Monitoring & Follow-up

  • Monitor for recurrence of CDI after treatment.

Risks

  • Potential risks include transmission of infectious agents and adverse reactions.

Patient & Prescribing Data

Children with recurrent CDI, particularly those unresponsive to antibiotics.

FMT is a viable alternative when conventional therapies fail.

Clinical Best Practices

  • Ensure thorough screening of stool donors to minimize infection risk.
  • Educate families about the benefits and risks of FMT.

Related Resources & Content

Original Source(s)

Related Content